CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 55 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Placebo 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02337634
NCT02337634Phase 2Completed
CompareCT.gov

Silymarin Treatment of Pathological Gambling: A Double-Blind, Placebo-Controlled Study

University of Chicago·interventional·Posted Jan 13, 2015·Updated Sep 4, 2024

In Brief

A Phase 2 clinical trial evaluating Placebo and Milk Thistle for Pathological Gambling and Gambling Disorder. Completed, enrolled 55 participants across 1 site.

Detailed Summary

The goal of the proposed study is to evaluate the efficacy and safety of silymarin in individuals with gambling disorder. The hypothesis to be tested is that silymarin will be more effective and well tolerated in subjects with gambling disorder compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPathological Gambling, Gambling Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJan 13, 2015
Enrollment StartJan 1, 2015
Primary CompletionDec 1, 2022
TodayJul 1, 2026
Enrollment to primary: 7.9 yearsPosted 11.5 years ago

Interventions

Placebodrug

Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.

Milk Thistledrug

Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.